Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

Table 2 Summary of molecular aberrations in genes, receptors and pathways by various CLIA certified methods in a patient with phyllodes tumor

	RAS/RAF/MAPK	P13CK/AKT/mTOR	Cell cycle/Apoptosis/Tumor Suppressor/Other pathways	Chemosensitivity markers
*CLIA Method,Lab and location*				Positive markers	Negative Markers
Foundation Next Gen Sequencing, Cambridge, Boston MA	NRAS Q61L		RB1 mutation and TP53 loss
aCGHCombimatrix Array, Irvine, CA			CKS1B amplification, TP53 loss
*IHC* –*Clarient,Aliso Viejo*, CA		p-AKT		PDGFR-α and β PTEN	Her-2
Morphoproteomics, UT Houston, TX		p-MTOR,		SPARC	ER-alpha
Caris Target Now, Irving, Tx				TLE3, ERCC1
*Potential Targeted therapy options*	MEK inhibitors	*P13CK/ AKT/* mTOR inhibitors	MEK inhibitors	Taxanes, albumin- bound paclitaxel; PDGFR inhibitors

Potential targeted therapy options based on best pre-clinical and/or clinical evidence are listed in the last row.

ISSN: 1750-1172